Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Terence Flynn has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising clinical data and competitive positioning in the market. The recent updates from ...

Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR ...

For reference, the recently approved CRISPR drug Casgevy costs $2.2 million for a course of treatment. Therefore, any ...

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on ...